Stoke Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of operations and comprehensive income (loss)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue	$10,632	$4,894	$183,018	$13,941
Operating expenses:
Research and development	37,696	22,205	96,227	65,710
Sales, general and administrative	16,027	12,692	45,942	35,950
Total operating expenses	53,723	34,897	142,169	101,660
Income (loss) from operations	(43,091)	(30,003)	40,849	(87,719)
Other income (expense):
Interest income (expense), net	3,463	3,545	10,141	9,668
Other income (expense), net	3	28	59	(448)
Total other income (expense)	3,466	3,573	10,200	9,220
Income (loss) before income taxes	$(39,625)	$(26,430)	$51,049	$(78,499)
Provision for income taxes	(1,278)	—	—	—
Net income (loss)	$(38,347)	$(26,430)	$51,049	$(78,499)
Net income (loss) per share:
Basic	$(0.65)	$(0.47)	$0.88	$(1.48)
Diluted	(0.65)	(0.47)	0.85	(1.48)
Weighted-average common shares outstanding:
Basic	58,611,677	56,341,074	58,278,812	52,991,015
Diluted	58,611,677	56,341,074	60,397,681	52,991,015
Comprehensive income (loss):
Net income (loss)	$(38,347)	$(26,430)	$51,049	$(78,499)
Other comprehensive gain (loss):
Unrealized gain on marketable securities	350	181	597	190
Total other comprehensive gain	$350	$181	$597	$190
Comprehensive income (loss)	$(37,997)	$(26,249)	$51,646	$(78,309)

Consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity
Shares · Amount
Balance as of December 31, 2023	45,918,233	$5	$561,433	$(24)	$(401,849)	$159,565
Unrealized gain on marketable securities	—	—	—	24	—	24
Stock-based compensation	—	—	5,410	—	—	5,410
Issuance of common stock upon exercise of stock options	79,682	—	250	—	—	250
Issuance of common stock related to employee stock purchase plan	37,542	—	168	—	—	168
Issuance of vested restricted stock units and performance stock units	190,350	—	—	—	—	—
Shares sold as part of controlled equity offering sales agreement, net of commissions	272,270	—	1,299	—	—	1,299
Net loss	—	—	—	—	(26,374)	(26,374)
Balance as of March 31, 2024	46,498,077	$5	$568,560	$—	$(428,223)	$140,342
Unrealized loss on marketable securities	—	—	—	(15)	—	(15)
Stock-based compensation	—	—	7,427	—	—	7,427
Issuance of common stock upon exercise of stock options	252,007	—	766	—	—	766
Issuance of common stock and warrants upon follow-on offering, net of underwriting discounts, commissions and offering costs	5,555,557	—	119,884	—	—	119,884
Net loss	—	—	—	—	(25,695)	(25,695)
Balance as of June 30, 2024	52,305,641	$5	$696,637	$(15)	$(453,918)	$242,709
Unrealized loss on marketable securities	—	—	—	181	—	181
Stock-based compensation	—	—	7,494	—	—	7,494
Issuance of common stock upon exercise of stock options	52,751	—	139	—	—	139
Issuance of common stock related to employee stock purchase plan	73,099	—	364	—	—	364
Shares sold as part of controlled equity offering sales agreement	509,700	—	7,656	—	—	7,656
Net loss	—	—	—	—	(26,430)	(26,430)
Balance as of September 30, 2024	52,941,191	$5	$712,290	$166	$(480,348)	$232,113

Stoke Therapeutics, Inc. and subsidiary continued

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.